Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook
at www.tipranks.com (Fri, 13-Mar 5:25 AM)
TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating
at www.tipranks.com (Tue, 10-Mar 7:55 AM)
TransMedics Secures Unconditional FDA IDE Approval for Historic OCS Heart ENHANCE Trial—Will This Redefine Heart Transplant Standards?
Market Chameleon (Mon, 9-Feb 9:02 AM)
